
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
Cooper Companies is well positioned in both the contact lens and women's health markets, with a diverse portfolio of products. The recent launch of Miudella, a hormone-free IUD, is expected to drive additional revenue and market share in the coming years. Additionally, the company's strong financial performance and potential strategic actions, such as a potential separation of its two business units, could serve as catalysts for its stock price. However, potential risks include competition in the contact lens market, economic weakness, and foreign currency fluctuations.
Bears say
Cooper Companies is facing pressure from potential increased competition in the IUD market, as evidenced by Paragard's expected decline in FY27 EPS contribution and the potential launch of a hormonal IUD by Sebela. Furthermore, while CooperSurgical sales grew in the latest quarter, there are concerns about consumer spending and potential softness in the fertility market, which could impact CSI's growth. The company's operating margin was also impacted by tariffs and unfavorable product mix, and while management expects a turnaround due to restructuring, there are risks to this projection. Overall, it may be difficult for Cooper Companies to sustain mid-single digit organic revenue growth and achieve high-single digit or better EPS growth in the near-term.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares